Credit rating of subsidiary Crosslay Remedies upgraded to AA+ by CARE

Rating UpgradedCredit & Debt View source PDF Explain this filing

MAXHEALTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹883.80

prior close

₹884.75

announcement price

After-mkt

timing

Nifty 100market-0.5%-1.5% vs market

Hospital peers, median of 25sector-0.8%-1.2% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty 100 and 1.2 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.3

15m

+0.5

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-0.5-1.5-0.8-1.2

Next day

-2.5+0.9-3.4-1.8-0.7

-3.5+0.6-4.1-1.7-1.8

-2.9+1.9-4.8-1.4-1.5

-4.3+2.5-6.8-1.8-2.5

-6.1+1.5-7.6-3.5-2.6

-7.6+0.4-7.9-5.0-2.5

15d

—————

UpDownMarket · Nifty 100Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CARE Ratings upgraded the credit rating of Max Healthcare's wholly-owned material subsidiary Crosslay Remedies Limited. The long-term bank facility rating moved from CARE AA- to CARE AA+ with a stable outlook. The short-term rating of CARE A1+ was reaffirmed and removed from Rating Watch with Positive Implications. Bank facility amounts were also enhanced, with the long-term portion rising from 1,000 crore to 1,211.80 crore rupees.

Likely market impact

Positive signal: stronger credit profile and higher facility limits for subsidiary, suggesting improved financial health and easier access to funds.